Tracers / [90Y]Y-90-FF-21101
[90Y]Y-90-FF-21101
Also written as Y-90-FF-21101
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- phase I/II clinical trial
- Syntheses indexed
- 2
What it is
- Compound class
- DOTA-conjugated chimeric human/mouse monoclonal antibody (radioimmunoconjugate)
- Target / mechanism
- Targets P-cadherin PMID 32737245
- Clinical application
- Radioimmunotherapy for P-cadherin-expressing advanced/metastatic solid tumors including ovarian carcinoma PMID 39748726
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | FF-21101 | 39748726 2025 Cancer |
| Manual synthesis | — | SPE | — | 99.3% ± 0.6% | FF-21101 (DOTA-conjugated chimeric human/mouse monoclonal antibody) Perseus Proteomics Inc. and Fujifilm Diosynth Biotechnologies U.S.A. Inc. | 32737245 2021 J Nucl Med The antibodies were incubated with 111InCl3 or 90YCl3 in 250 mM sodium acetate (pH 5.5) for 15 min at 45°C and purified with phosphate-buffered saline (PBS, pH 7.4) using NAP-5 columns |
Need this precursor?We can point you to suppliers for [90Y]Y-90-FF-21101, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 39748726: 'A previously reported, first-in-human study determined that a dose of 25 mCi/m2 was safe, and a patient with clear cell carcinoma of the ovary achieved a complete response.'.